ACET

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States.

The company’s lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases.

It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen.

The company was founded in 2014 and is based in Boston, Massachusetts.